Related Experiment Video

Updated: Jul 9, 2026

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
08:02

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice

Published on: October 19, 2013

Phosphodiesterase-4 inhibition attenuates pulmonary inflammation in neonatal lung injury

Y P de Visser1, F J Walther, E H Laghmani

  • 1Dept of Pediatrics, Division of Neonatology, P3-P30, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.

The European Respiratory Journal
|December 21, 2007
PubMed

Insights

Phosphodiesterase-4 (PDE4) inhibitors, like piclamilast, improved survival in pre-term rat pups with lung injury. PDE4 inhibition reduced inflammation and fibrin deposition, suggesting therapeutic potential for bronchopulmonary dysplasia.

Area of Science:

  • Pulmonary Medicine
  • Pharmacology
  • Neonatology

Background:

  • Phosphodiesterase-4 (PDE4) inhibitors are explored for respiratory diseases like asthma and COPD.
  • Bronchopulmonary dysplasia (BPD) is a significant concern in premature infants, necessitating novel therapeutic strategies.
  • Selective PDE4 inhibitors may offer a therapeutic option for BPD.

Purpose of the Study:

  • To investigate the anti-inflammatory effects of two PDE4 inhibitors, rolipram and piclamilast, in a pre-term rat model of hyperoxia-induced lung injury.
  • To assess the impact of prolonged PDE4 inhibitor therapy on survival, lung pathology, and key gene expression in experimental BPD.

Main Methods:

  • Pre-term rat pups were exposed to room air, hyperoxia, or hyperoxia plus rolipram or piclamilast.
  • Evaluated survival, histopathology, fibrin deposition, alveolar vascular leakage, and differential mRNA expression (real-time RT-PCR) of genes related to inflammation, coagulation, and fibrinolysis.

Main Results:

  • PDE4 inhibitor therapy extended median survival by up to 7 days.
  • Reduced alveolar fibrin deposition, lung inflammation, and vascular leakage.
  • Decreased monocyte/macrophage influx and protein efflux in bronchoalveolar lavage fluid.
  • Significant improvement in mRNA expression of genes involved in inflammation, fibrin deposition, and alveolarization.

Conclusions:

  • Phosphodiesterase-4 inhibition prolongs survival in pre-term rat pups with neonatal hyperoxic lung injury.
  • PDE4 inhibition effectively reduces inflammation and alveolar fibrin deposition.
  • Piclamilast demonstrated superior efficacy compared to rolipram in this model.

More Related Videos

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation07:40

A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation

Published on: August 30, 2019

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: